A clinical-stage biotechnology company working on diseases caused by misfolded proteins, including Parkinson's disease, where its lead drug candidate GT-02287 aims to help restore a key enzyme. Founded in 2017 in Lugano, Switzerland, it uses its AI-driven Magellan platform to spot hard-to-reach spots on disease-related proteins. The name reflects the goal of "gaining" control over protein function—and access to pockets long considered undruggable.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +128.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.